canada clinical guidance

Depression

A Canadian clinical summary of depression, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by 2023 update on clinical guidelines for management of major depressive disorder in adults. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CANMAT MDD

Source-attributed clinical priorities

  • Assess suicide risk, bipolar-spectrum features, psychosis, substance use, medical contributors and functional impairment before selecting treatment.
  • Match psychotherapy, pharmacotherapy and combined care to severity, prior response, preference, comorbidity and access.
  • Measure symptoms and function during follow-up, optimize an adequate trial and use the CANMAT sequence when response is insufficient.
  • Ask directly about previous hypomania or mania because an unrecognized bipolar course changes treatment selection.
sources for this section:CANMAT MDD

Practical assessment and management workflow

1
Record baseline depressive symptoms, functioning, sleep, appetite, cognition and safety with a reproducible measure.
2
Clarify episode duration, recurrence, seasonality, perinatal context, medications and relevant physical illness.
3
Agree on psychotherapy, medication, exercise and social interventions that are feasible for the person.
4
Review early for tolerability and safety, then document remission, residual symptoms and relapse-prevention needs.
sources for this section:CANMAT MDD

Safety, red flags and urgent escalation

  • Arrange urgent assessment for imminent suicide risk, psychotic depression, catatonia or inability to maintain nutrition and hydration.
  • Monitor for activation, emergent suicidality, serotonin toxicity, withdrawal and medication interactions.
  • Do not stop an effective antidepressant abruptly; plan a gradual, monitored change when discontinuation is chosen.
sources for this section:CANMAT MDD

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CANMAT MDD

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CANMAT MDD

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Network for Mood and Anxiety Treatments2023 update on clinical guidelines for management of major depressive disorder in adultsaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.